We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gene Logic Inc. and Organon announced today that they have entered into a drug repositioning agreement to seek alternative development paths for multiple drug candidates of which Organon has previously discontinued clinical development.
SkyePharma PLC announces today that it has agreed with its North American partner Endo Pharmaceuticals to terminate the joint development of Propofol IDD-D, an injectable anaesthetic and sedative that was licensed to Endo in December 2002.
With Novartis' application to market a generic version of Pfizer's Genotropin in the EU having recently been approved, the European Commission has voiced its support for biosimilars.
Israel-based Predix Pharmaceuticals has completed a Phase Ib clinical study of PRX-08066, a drug for pulmonary arterial hypertension (PAH), in 15 adults.
Researchers at the University at Buffalo have identified a novel agent that can protect neurons involved in Parkinson's disease from being destroyed by the pesticide rotenone.
Concurrent administration of propafenone and ibutilide -- both used to treat cardiac arrhythmia -- for the treatment of persistent atrial fibrillation (AF) is more effective than treatment with ibutilide alone, according to a study published in the British medical journal Heart.
Japanese drugmakers Shionogi and Nippon Kayaku have been granted approval for Cetrotide, an agent for preventing premature ovulation, from the country's Ministry of Health, Labor and Welfare, the companies announced.
Talks between the government and pharmaceutical companies have been suspended prior to the elections; as a result, no agreement is possible before the new government swears in, Krisztina Székely, President of the Innovative Pharmaceutical Manufacturers' Association told Portfolio.hu.
Techedge Inc. announced that China BioPharma, Ltd. has appointed Dr. Yimin Yu, the current Chairman of HYTE Research, LLC to the company's Board of Advisors.
Eli Lilly & Co. (LLY) Chief Operating Officer John C. Lechleiter said Thursday that sales of the company's drug Zyprexa are down, which will have an impact on the company's second quarter.